Celator Pharmaceuticals has reached 50% enrollment in its Phase III study comparing CPX-351 (cytarabine:daunorubicin) Liposome Injection versus the conventional cytarabine and daunorubicin treatment regimen (commonly referred to as 7+3) as first-line therapy in older patients with high-risk (secondary) acute myeloid leukemia (AML). Planned enrollment is 300 patients. The Phase III study is being conducted in partnership with The Leukemia & Lymphoma Society (LLS) through its Therapy Accelera...